Three poster presentations will provide full details of the PREVA trial and include
A report on the randomized phase
A report on the open label phase
An analysis of quality of life impact
On Saturday evening electroCore is hosting a satellite symposium with three eminent headache specialists.
electroCore, a US based company, has developed non-invasive Vagus Nerve Stimulation (nVNS) therapies, which are self-administered by patients for the treatment of multiple conditions in neurology, psychiatry, respiratory and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in gastric motility disorders and epilepsy.
In Europe, electroCore’s nVNS technology has a CE mark for primary headache, bronchoconstriction, epilepsy, gastric motility disorders, and anxiety and depression. It also has regulatory approval for the acute and/or prophylactic treatment of cluster headache, migraine and medication overuse headache in South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia, and in Canada for cluster headache. US approval is anticipated in 2015.
*European Headache and Migraine Trust International Congress